Hybrid financing structures are helping catalyze sector growth and value creation, giving investors earlier, less crowded access to life sciences and MedTech operators. Blended finance approaches are helping companies secure better pricing and deal terms, de-risk investments, and position investors for significant upside when market favorability returns. And as life sciences mergers and acquisitions (M&A) accelerate and buyers look to acquire earlier in the development cycle, hybrid financing has become a critical bridge to acquisition — giving target companies the capital influx needed while providing investors structured protections and multiple paths to liquidity.
Read the full article: Hybrid Financing in Life Sciences: Unlocking Growth Amid Market Challenges //
Source: https://www.lexology.com/library/detail.aspx?g=0bb6b28b-fb9f-4b7b-b13e-07b784779b28